Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 18, 2012

EMD Millipore Negotiates Access to iPSC Patents

  • EMD Millipore acquired a nonexclusive license to iPS Academia Japan’s (AJ) induced pluripotent stem cell (iPSC) patent portfolio, for the development and commercialization of iPSCs for research applications. AJ’s patent portfolio is founded on work by Shinya Yamanaka M.D., at the Center for iPS Cell Research and Application at Kyoto University, to which AJ is an affiliate.

    The four cell reprograming factors discovered by Dr. Yamanaka are integral to Millipore’s existing Stemcca™ reprogramming kit for generating human and mouse iPSCs, which uses a single, excisable polycistronic lentiviral vector to deliver the factors.

    Under terms of the new licensing deal Millipore will continue to offer the Stemcca kits for research applications. “To collaborate with the founder of iPS cell discovery provides the ideal opportunity for EMD Millipore to build upon our current product offering of the Stemcca reprogramming kits, as well as further advance our research and discovery in the area of stem cell technology, and to provide our customers with the tools necessary in this important, breakthrough area of stem cell research,” states John Sweeney, head of Millipore’s bioscience business unit.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »